Oramed Pharmaceuticals SG&A Expenses 2011-2024 | ORMP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Oramed Pharmaceuticals sg&a expenses from 2011 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Oramed Pharmaceuticals sg&a expenses from 2011 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$200B
Stryker (SYK)	$141B
Boston Scientific (BSX)	$128B
Medtronic (MDT)	$113B
EssilorLuxottica (ESLOY)	$112.7B
Lonza Group Ag (LZAGY)	$45.3B
Haleon (HLN)	$43.5B
GE HealthCare Technologies (GEHC)	$40.4B
ResMed (RMD)	$36.5B
Terumo (TRUMY)	$30.3B
Koninklijke Philips (PHG)	$25.9B
Zimmer Biomet Holdings (ZBH)	$21.6B
Baxter (BAX)	$18.4B
Insulet (PODD)	$17.2B
Smith & Nephew SNATS (SNN)	$10.8B
Bio-Rad Laboratories (BIO)	$10.4B
BellRing Brands (BRBR)	$8.9B
Demant (WILYY)	$8.4B
Lantheus Holdings (LNTH)	$6.1B
Haemonetics (HAE)	$4.4B
ICU Medical (ICUI)	$4.4B
TG Therapeutics (TGTX)	$4.3B
Prestige Consumer Healthcare (PBH)	$4B
Envista Holdings (NVST)	$3.7B
Perrigo (PRGO)	$3.7B
Neogen (NEOG)	$3.4B
Agios Pharmaceuticals (AGIO)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.9B
QuidelOrtho (QDEL)	$2.6B